Shares outstanding of Coherus BioSciences, Inc.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|MTNB Matinas Biopharma Holdings, Inc.||NYSEMKT > Health Care > Major Pharmaceuticals||5.40|
|CFMS ConforMIS, Inc.||NASDAQ > Health Care > Industrial Specialties||5.41|
|NRE NorthStar Realty Europe Corp.||NYSE > Consumer Services > Real Estate Investment Trusts||5.42|
|TIF Tiffany & Co.||NYSE > Consumer Services > Consumer Specialties||5.44|
|LGL LGL Group, Inc. (The)||NYSEMKT > Capital Goods > Industrial Machinery/Components||5.44|
|NANO Nanometrics Incorporated||NASDAQ > Capital Goods > Industrial Machinery/Components||5.45|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||5.46|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||297.63|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||762.43|
|WMIH WMIH Corp.||NASDAQ > Finance > Finance: Consumer Services||812.31|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||966.10|
|HUNT Hunter Maritime Acquisition Corp.||NASDAQ > Transportation > Oil Refining/Marketing||1,687.50|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|